Background Data on the epidemiology of hepatitis B and C in Bosnia and Herzegovina (B&H) are lacking. Objectives To assess the prevalence of hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus (anti-HCV) in blood samples of first time blood donors in a well-defined region of B&H. Our secondary goal was to estimate the prevalence of HBsAg and anti-HCV in the general population of the same region. Patients and Methods We evaluated 8196 blood samples for the presence of HBsAg and/or anti-HCV, adjusted for differences in gender, and used the ratio estimation method to determine the prevalence in the general population. Results We analyzed 1263 (15.4%) female and 6933 (84.6%) male blood donors (male-to-female ratio: 5.49 to 1). The adjusted prevalence of HBsAg among blood donors was 0.787% (95% CI = 0.535-1.038), while the prevalence of anti-HCV was 0.267% (95% CI = 0.016-0.519). There was no difference in the prevalence of HBsAg or anti-HCV between men and women. We estimate that the prevalence of HBsAg and anti-HCV in the general population is 1.057% to 1.535% and 0.29% to 0.89%, respectively. Conclusions The prevalence of HBsAg and anti-HCV among blood donors suggests that our region has low endemicity for both hepatitis B and hepatitis C.

Background Data on the epidemiology of hepatitis B and C in Bosnia and Herzegovina (B&H) are lacking. Objectives To assess the prevalence of hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus (anti-HCV) in blood samples of first time blood donors in a well-defined region of B&H. Our secondary goal was to estimate the prevalence of HBsAg and anti-HCV in the general population of the same region. Patients and Methods We evaluated 8196 blood samples for the presence of HBsAg and/or anti-HCV, adjusted for differences in gender, and used the ratio estimation method to determine the prevalence in the general population. Results We analyzed 1263 (15.4%) female and 6933 (84.6%) male blood donors (male-to-female ratio: 5.49 to 1). The adjusted prevalence of HBsAg among blood donors was 0.787% (95% CI = 0.535-1.038), while the prevalence of anti-HCV was 0.267% (95% CI = 0.016-0.519). There was no difference in the prevalence of HBsAg or anti-HCV between men and women. We estimate that the prevalence of HBsAg and anti-HCV in the general population is 1.057% to 1.535% and 0.29% to 0.89%, respectively. Conclusions The prevalence of HBsAg and anti-HCV among blood donors suggests that our region has low endemicity for both hepatitis B and hepatitis C.

Background Data on the epidemiology of hepatitis B and C in Bosnia and Herzegovina (B&H) are lacking. Objectives To assess the prevalence of hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus (anti-HCV) in blood samples of first time blood donors in a well-defined region of B&H. Our secondary goal was to estimate the prevalence of HBsAg and anti-HCV in the general population of the same region. Patients and Methods We evaluated 8196 blood samples for the presence of HBsAg and/or anti-HCV, adjusted for differences in gender, and used the ratio estimation method to determine the prevalence in the general population. Results We analyzed 1263 (15.4%) female and 6933 (84.6%) male blood donors (male-to-female ratio: 5.49 to 1). The adjusted prevalence of HBsAg among blood donors was 0.787% (95% CI = 0.535-1.038), while the prevalence of anti-HCV was 0.267% (95% CI = 0.016-0.519). There was no difference in the prevalence of HBsAg or anti-HCV between men and women. We estimate that the prevalence of HBsAg and anti-HCV in the general population is 1.057% to 1.535% and 0.29% to 0.89%, respectively. Conclusions The prevalence of HBsAg and anti-HCV among blood donors suggests that our region has low endemicity for both hepatitis B and hepatitis C.

Background: Accurate estimations of hepatitis B virus transmission risk for any region in Bosnia and Herzegovina are not clearly established. We aimed to determine levels of risk associated with intrafamilial transmission of hepatitis B infection within families in our region. Patients and Methods: Family members of 81 chronic carriers of hepatitis B surface antigen (>6 months positive and considered as index case) were tested for hepatitis B markers. For family members, we recorded their age, sex, and family relationship to the index case, and vaccination status. Results: The proportion of HBsAg positive family members was 25/207 (12.1%), while the proportion of family members with evidence of exposure to HBV was 80/207 (38.6%). Only 17/207 (8.2%) family members had evi--dence of past HBV vaccination. Age was found to be a significant predictor of HBV exposure of family members (odds ratio 1.05, 95% CI 1.03-1.07, P< .001). In a multivariate analysis, HBsAg positivity was associated with a female index case (odds ratio 11.31, 95% CI 3.73-34.32, P< .001), HBeAg positivity in the index case (odds ratio 5.56, 95% CI 1.80-17.23, P< .005) and being a mother of the index case (odds ratio 9.82, 95% CI 2.43-39.68,P< .005). A female index case (odds ratio 4.87, 95% CI 2.21-10.72, P< .001), HBeAg positivity in the index case (odds ratio 3.22, 95% CI 1.15-9.00, P< .05) and being a mother of the index case (odds ratio 3.72, 95% CI 1.19-11.64, P< .05) were also risk factors for HBV exposure among family members. The combination of HBeAg positivity and female index case was a significant predictor for HBsAg positivity of family members (odds ratio 70.39, 95% CI 8.20-604.61, P< .001). Conclusions: Children of HBeAg positive mothers are at highest risk for becoming chronic carriers them--selves and generally, the combination of female sex and HBeAg positivity dramatically increases the chances of HBV transmission within the family.

Retrospektivno su analizirane klini~ke i epidemiolo{ke karakteristike bruceloze u 91 bolesnika koji su bili hospitalizirani u Klinici za infektivne bolesti u Tuzli od 1.1.2000. godine do 1.8.2008. godine. Definitivna dijagnoza bruceloze postavljena je na temelju pozitivnih rezultata hemokulture i/ili nekog od relevantnih serolo{kih testova (ELISA test, ROSE-BENGAL aglutinacija). Ve}ina bolesnika bila je iz 5 op}ina Tuzlanskog kantona: @ivinice, Tuzla, Lukavac, Kalesija, i Srebrenik, ukupno (81,3 %) bolesnika. Najve}i broj bolesnika (93 %) bio je iz ruralne regije. Bilo je znatno vi{e mu{karaca (82,4 %). Ve}ina bolesnika bila je u dobi od 20 – 29 godina i 50 – 59 godina po 25,3 %. Najvi{e bolesnika bilo je hospitalizirano u proljetnim mjesecima, travnju 24,1% i svibnju 23,0 %. Kontakt s inficiranim `ivotinjama registriran je kod 82,4 % bolesnika. Vode}i simptomi i znaci bolesti bili su povi{ena temperatura, bolovi u zglobovima, op}a slabost, no}no znojenje, glavobolja, hepatosplenomegalija, a najva`niji patolo{ki laboratorijski nalazi ubrzana sedimentacija eritrocita i povi{ena vrijednost C-reaktivnog proteina. Bolesnici su lije~eni kombinacijom streptomicina ili gentamicina s doksiciklinom u odraslih, ili gentamicinom i trimetoprim-sulfametoksazolom u djece, u trajanju 6 tjedana. Komplikacije su dokumentirane u 23,0 % mu{karaca i 1,1 % `ena. Orchiepididimitis je utvr|en u 6,5 %, pneumonija 4,3 %, periferni artritis 4,3%, spondilitis 3,2 %, sakroileitis 2,1 %, epiduralni absces u 2,1 % i spondilodiscitis u 1 % bolesnika. Relaps je zabilje`en u 13,1 % bolesnika. Svi bolesnici su izlije~eni. Bruceloza je rastu}i javno-zdravstveni problem u Tuzlanskom kantonu, ali i {ire u Bosni i Hercegovini.